Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

NCT01606800 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
45
Enrollment
INDUSTRY
Sponsor class

Stopped The trial was terminated due to change in new standard of therapy during the study period.

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC